[Expression of BRAF V600E mutation in different thyroid lesions].

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Context:

• Thyroid cancer is a significant health concern, with papillary thyroid carcinoma (PTC) being the most common subtype.
• The BRAF V600E mutation is a known oncogenic driver in various cancers, including thyroid cancer.
• Accurate detection and understanding of genetic alterations are crucial for diagnosis and prognosis.

Purpose:

• To investigate the prevalence and significance of the BRAF V600E mutation in a cohort of Chinese patients with diverse thyroid lesions.
• To assess the association of BRAF V600E mutation with different types of thyroid neoplasms.
• To evaluate the utility of BRAF V600E mutation detection as a prognostic indicator for PTC.

Summary:

• BRAF V600E mutation was detected in 25.4% of 240 Chinese patients with thyroid lesions.
• The mutation was exclusively found in papillary thyroid carcinoma (PTC) cases (47.3%), with a higher prevalence in the classic subtype (49.6%) compared to the follicular subtype (12.5%).
• No significant correlation was observed between BRAF V600E mutation and clinicopathological parameters in PTC.

Impact:

• The findings highlight the strong association between BRAF V600E mutation and PTC in the Chinese population.
• Detection of BRAF V600E mutation can serve as a valuable prognostic biomarker for PTC.
• The study also validates an efficient and cost-effective DNA extraction method from paraffin-embedded tissues for mutation analysis.